An alternative pharmacological approach to mitigate metabolic dysfunction in obesity might be to selectively enhance protective IRE1/XBP1s signaling without inducing the pathologic aspects associated with IRE1 hyperactivity (e.g., TRAF2-mediated JNK activation)10,25,26. Here, ERN1 is linked to obesity disorder.